
Curis, Inc.
- Jurisdiction
United States - LEI
5299000YO6CX4WMFVX06 - ISIN
US2312693094 (CRIS )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Read full profile
Stock price
Fundamentals
- Net revenue
€9.83M - Gross margin
99.3% - EBIT
-€32.71M - EBIT margin
-332.9% - Net income
-€33.53M - Net margin
-341.2%
Statement period: - (published )
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: May 7, 2024
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Buy |